These findings suggest that combination therapies are needed, e.g., if using a TLR agonist or BCG, one might pre-emptively combine it with anti-PD-1 or anti-CD47 to block the predictable counterattack of the tumor (PD-L1, CD47 upregulation). Here, CD47 is linked to neoplasm.